Scientists unlock secrets of flu Vaccine's age gap
NCT ID NCT06501963
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at why the live attenuated influenza vaccine (LAIV), given as a nasal spray, is less effective in adults than in children. Researchers measured antibody levels in 51 healthy adults after vaccination to understand the immune response. The goal is to use these insights to design better flu vaccines for everyone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Live attenuated influenza vaccine (FluMist nasal spray)
- What this could lead to
- If successful, this research could help design more effective flu vaccines for adults.
- What could go wrong
- This is a small, completed study focused on understanding immune responses, not testing a new treatment. Results may not directly lead to better vaccines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
51 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Apr 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 49 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Able to understand and give informed consent * Participants of child bearing potential must agree to use effective birth control for the duration of the study. A negative urine pregnancy test must be documented prior to vaccination. Exclusion Criteria: * History of allergy or serious adverse reaction, including Guillain-Barré syndrome, to a vaccine or vaccine products * History of a medical condition resulting in impaired immunity such as active solid tumors, leukemia, lymphoma, chemotherapy or radiation therapy, autoimmune conditions, or splenic dysfunction. Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study. * History of asthma, cochlear implant, or active cerebrospinal fluid leak * Use of immune modifying drugs including: systemic steroids for more than 1 week (such as prednisone \> 20mg/day), chronic administration (more than 14 days total) of immunosuppressive or immunomodulatory drugs in the prior 3 months * History of HIV, Hepatitis B or Hepatitis C infection * Chronic clinically significant medical problems that could be considered active or unstable (i.e diagnosed within the past 3 months or requiring a change in medication within the past 3 months). This is including (but not limited to): * Insulin dependent diabetes * Severe heart disease (including arrhythmias) * Severe lung disease * Severe liver disease * Severe kidney disease * Severe hypertension: defined as life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit). * Congenital genetic syndromes (e.g., trisomy 21) * Body Mass Index (BMI) \> 35 * Pregnancy or breast feeding, or plans to become pregnant in the next month * History of influenza infection or vaccination within the current or previous influenza season * Receipt of blood products or immune globulin product within the prior 3 months * History of excessive alcohol consumption, drug use, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial * Receipt of any live vaccines 30 days before, or plans to receive any live vaccines 30 days after vaccination * Receipt of any inactivated vaccines 14 days before, or plans to receive any inactivated vaccines 14 days after vaccination * Receipt of any non-registered or other investigational product in 30 days before, or plans to receive any other investigational product 30 days after vaccination * Temporary Exclusion Criteria: * Fever (temperature ≥38.0°C) or coryzal symptoms within 72 hours prior to vaccination * Receipt of antipyretics within 6 hours prior to vaccination
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Influenza are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hope Clinic of the Emory Vaccine Center
Decatur, Georgia, 30030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- When the immune system Can't fight back: tracking three respiratory viruses
- Flu's journey: scientists track how influenza passes between people
- Can a stronger flu shot boost immunity in older adults?
- A nudge in the mailbox: could a letter boost flu shots for millions at risk?
- Can a new pill shorten the flu?
- Can a texted story boost flu shots for black kids?